NCT04294628: Testing the Biological Effects of DS-8201a on Patients With Advanced Cancer

NCT04294628
Breast Cancer Type: HER2+
Hormone Mutations: ER+, PR+
Other Mutations: HER2-low, HER2
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: Brain
Additional Notes: Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression for greater than or equal to 1 month after treatment of the brain metastases
Exclusions: Patients with clinically active central nervous system metastases, defined as untreated & symptomatic, or requiring therapy
https://ClinicalTrials.gov/show/NCT04294628

Comments are closed.

Up ↑